Psychopharmacology Practice Questions

Q: What is the therapeutic serum level of lithium in acute mania?

0.8-1.5 mEq/L. **Explanation:** Lithium is the gold-standard mood stabilizer used for the treatment of Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small, necessitating regular Therapeutic Drug Monitoring (TDM). 1. **Why Option B is Correct:** In the **acute phase of mania**, higher serum levels are required to control symptoms effectively. The established therapeutic range is **0.8 to 1.2 mEq/L** (often extended up to **1.5 mEq/L** in severe cases). Once the patient is stabilized, the maintenance dose is lower, typically **0.6 to 1.2 mEq/L**. 2. **Why Other Options are Incorrect:** * **Option A (0.2-0.5 mEq/L):** These levels are sub-therapeutic and will not provide clinical improvement in mania. * **Option C (1-2 mEq/L):** While it overlaps with the therapeutic range, levels above 1.5 mEq/L are generally considered the threshold for early toxicity. * **Option D (2-5 mEq/L):** These are toxic levels. Levels >2.0 mEq/L indicate severe toxicity, and levels >3.5 mEq/L are life-threatening emergencies requiring hemodialysis. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Blood for TDM should be drawn **12 hours after the last dose** (Steady-state is reached in 4-5 days). * **Side Effects:** Most common acute side effect is **fine tremors**; most common endocrine side effect is **hypothyroidism**. * **Teratogenicity:** Causes **Ebstein’s Anomaly** (atrialization of the right ventricle) if taken during pregnancy. * **Toxicity Precipitants:** Dehydration, low sodium intake, and drugs like **NSAIDs, Thiazides, and ACE inhibitors** can increase lithium levels.

Q: The procedure shown below is used in all of the following illnesses except:

Dissociative disorder. ***Dissociative disorder*** - **ECT is not indicated** for dissociative disorders as they are primarily treated with **psychotherapy** and **trauma-focused interventions**. - Dissociative disorders involve disruptions in **consciousness, memory, identity**, and do not respond to **neurobiological interventions** like ECT. *Catatonic schizophrenia* - **ECT is highly effective** for catatonic symptoms, especially **catatonic stupor** and **malignant catatonia**. - Provides rapid relief when **antipsychotics** fail or when **life-threatening complications** like hyperthermia occur. *Treatment-resistant major depressive disorder* - **ECT is the gold standard** for severe depression that fails to respond to **multiple antidepressant trials**. - Shows **response rates of 70-90%** in treatment-resistant cases and is particularly effective for **psychotic depression**. *Severe mania* - **ECT is indicated** for severe manic episodes, especially with **psychotic features** or **catatonic symptoms**. - Used when **mood stabilizers** are ineffective or contraindicated, providing rapid **mood stabilization**.

Q: A 28-year-old woman with bipolar disorder has a lithium level of 2.3 mEq/L (normal range 0.6-1.25 mEq/L). Which of the following side effects is most likely to occur?

tremor. **Explanation:** The patient presents with **Lithium Toxicity**, as evidenced by a serum lithium level of **2.3 mEq/L**. The therapeutic range for lithium is narrow (0.6–1.2 mEq/L), and levels above 1.5 mEq/L are generally considered toxic. **Why Tremor is Correct:** Tremors are a hallmark side effect of lithium. While a **fine resting tremor** can occur at therapeutic doses, a **coarse (gross) intention tremor** is a classic sign of worsening lithium toxicity. As levels rise (especially >2.0 mEq/L), neurological symptoms become prominent, including ataxia, dysarthria, confusion, and seizures. **Analysis of Incorrect Options:** * **A & B (Mania/Depression):** Lithium is a mood stabilizer used to *treat* these conditions. While toxicity indicates the drug is at dangerous levels, it does not typically trigger an acute switch into mania or depression; rather, it causes systemic and neurological dysfunction. * **D (Hyponatremia):** Lithium does not cause hyponatremia; instead, **hyponatremia causes lithium toxicity**. Because lithium is handled by the kidneys similarly to sodium, low sodium levels lead to increased proximal tubule reabsorption of lithium, raising serum levels to toxic ranges. **NEET-PG High-Yield Pearls:** * **Therapeutic Range:** 0.6–1.2 mEq/L (Prophylaxis: 0.6–0.8; Acute Mania: 0.8–1.2). * **Toxicity Levels:** >1.5 (Mild), >2.0 (Moderate), >3.5 (Severe/Life-threatening). * **Management:** For levels >2.5 mEq/L (or >4.0 in chronic users), **Hemodialysis** is the treatment of choice. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase lithium levels (the "TAN" mnemonic). * **Early Sign of Toxicity:** Persistent GI upset (nausea/vomiting) often precedes neurological signs.

Q: Who introduced lithium for the treatment of manic-depressive illness?

John F. Cade. **Explanation:** The correct answer is **John F. Cade**. In **1949**, Australian psychiatrist John Cade discovered the antimanic effects of lithium while researching the role of uric acid in psychotic patients. He observed that lithium urate had a calming effect on guinea pigs, leading him to successfully treat patients with chronic and acute mania. This discovery marked the beginning of the modern era of psychopharmacology. **Analysis of Incorrect Options:** * **Benedict Morel (A):** He is known for introducing the term *"Démence précoce"* (the precursor to the term Schizophrenia) to describe a condition of mental deterioration starting in adolescence. * **Delay and Deniker (B):** Jean Delay and Pierre Deniker are credited with discovering the antipsychotic properties of **Chlorpromazine** in 1952, which revolutionized the treatment of schizophrenia. * **Eugen Bleuler (D):** He coined the term **"Schizophrenia"** (replacing Morel’s term) and defined its core symptoms using the "4 As" (Ambivalence, Autism, Affective flattening, and Association looseness). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Lithium acts by inhibiting the **Inositol Monophosphatase (IMPase)** pathway and GSK-3 enzyme. * **Therapeutic Index:** It has a narrow therapeutic index. Target serum levels are **0.8–1.2 mEq/L** for acute mania and **0.6–0.8 mEq/L** for maintenance. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (tricuspid valve abnormality). * **Side Effects:** Common high-yield side effects include fine tremors, polyuria (nephrogenic diabetes insipidus), and hypothyroidism.

Q: Which of the following drugs are used for recurrent depressive episodes?

Fluoxetine. **Explanation:** The core management of **Recurrent Depressive Disorder (RDD)** involves the use of antidepressants to achieve remission and prevent future relapses. **Why Fluoxetine is Correct:** Fluoxetine is a **Selective Serotonin Reuptake Inhibitor (SSRI)**. SSRIs are the first-line pharmacological treatment for depressive episodes due to their superior safety profile, better tolerability, and lower side-effect burden compared to older classes. For recurrent episodes, maintenance therapy with an effective antidepressant (like Fluoxetine) is indicated for at least 2 years or longer to prevent recurrence. **Analysis of Incorrect Options:** * **Imipramine (Option A):** While Imipramine is a Tricyclic Antidepressant (TCA) and effective for depression, it is no longer the first-line choice due to significant side effects (anticholinergic, sedative, and cardiotoxicity in overdose). * **Carbamazepine (Option B) & Valproate (Option D):** These are **Mood Stabilizers** (Anticonvulsants). They are primarily used in the treatment of Bipolar Disorder (to treat mania and prevent mood swings) rather than unipolar recurrent depression. **High-Yield Clinical Pearls for NEET-PG:** * **Maintenance Duration:** After a single episode of depression, continue treatment for 6–9 months. For recurrent episodes (2 or more), continue for at least 2 years. * **Drug of Choice (DOC):** SSRIs are the DOC for Depression, Panic Disorder, OCD, and Social Phobia. * **Fluoxetine Specifics:** It has the longest half-life among SSRIs (due to its active metabolite norfluoxetine), making it the safest option if a patient occasionally misses a dose, but it requires a longer washout period before starting an MAOI to avoid **Serotonin Syndrome**. * **Prophylaxis:** If a patient has had 3 or more episodes, lifelong prophylaxis is often recommended.

Q: Which of the following conditions increases the chance of hyponatremia in a patient treated with an antidepressant?

Old age. **Explanation:** The development of hyponatremia is a well-recognized side effect of antidepressant therapy, particularly with **Selective Serotonin Reuptake Inhibitors (SSRIs)** and **Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)**. **1. Why Old Age is Correct:** The primary mechanism is the **Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH)**. Antidepressants can stimulate the release of ADH or increase the sensitivity of the kidneys to it, leading to water retention and dilutional hyponatremia. **Old age** is the most significant risk factor because elderly patients often have decreased total body water, age-related changes in renal function, and are frequently on concomitant medications (like diuretics or NSAIDs) that further impair water excretion. **2. Analysis of Incorrect Options:** * **Low weight:** While some studies suggest low body mass index (BMI) might be a minor risk factor, it is not as clinically significant or consistently proven as advanced age. * **Cold climate:** Climate does not influence the pathophysiology of SIADH or antidepressant-induced hyponatremia. * **Obesity:** Obesity is not a recognized risk factor for SIADH; in fact, the risk is generally higher in those with lower body weight/frailty. **Clinical Pearls for NEET-PG:** * **Most Common Culprits:** SSRIs (Fluoxetine, Sertraline, Paroxetine) are the most frequently implicated. * **Timing:** Hyponatremia typically develops within the **first 2–4 weeks** of starting treatment. * **Monitoring:** Always check baseline and follow-up electrolytes in elderly patients starting SSRIs. * **Symptoms:** Range from lethargy and confusion to seizures and coma if sodium levels drop rapidly.

Q: What adverse effect can sodium valproate cause in a patient with bipolar mood disorder?

Hepatotoxicity. **Explanation:** **Sodium Valproate** is a broad-spectrum antiepileptic drug also used as a first-line mood stabilizer in Bipolar Mood Disorder. **Why Hepatotoxicity is the Correct Answer:** Valproate is metabolized in the liver. Its most serious and potentially fatal adverse effect is **idiosyncratic hepatotoxicity**. This typically occurs within the first six months of therapy. It is caused by the formation of toxic metabolites (like 4-pentenoic acid) that interfere with mitochondrial beta-oxidation. Risk is highest in children under two years old and those on polytherapy, but it remains a critical monitoring parameter for all psychiatric patients on long-term valproate. **Analysis of Incorrect Options:** * **A. Peripheral neuropathy:** This is more commonly associated with drugs like **Phenytoin** or **Isoniazid**, not Valproate. * **B. Renal failure:** Valproate is not nephrotoxic. In contrast, **Lithium** (another mood stabilizer) is known for causing nephrogenic diabetes insipidus and chronic interstitial nephritis. * **D. Cystitis:** Specifically **Hemorrhagic Cystitis** is a classic side effect of **Cyclophosphamide** (due to acrolein), not valproate. **High-Yield NEET-PG Pearls:** * **Teratogenicity:** Valproate is highly teratogenic, causing **Neural Tube Defects** (specifically Spina Bifida) due to interference with folate metabolism. * **Other Side Effects:** Remember the mnemonic **VALPROATE**: **V**omiting, **A**lopecia (transient), **L**iver toxicity, **P**ancreatitis (acute), **R**etention of weight (Weight gain), **O**edema, **A**ppetite increase, **T**hrombocytopenia, and **E**ncephalopathy (due to hyperammonemia). * **Monitoring:** Baseline and periodic **Liver Function Tests (LFTs)** are mandatory.

Q: Tardive dyskinesia is least common with which of the following medications?

Olanzapine. **Explanation:** The risk of **Tardive Dyskinesia (TD)** is directly related to the potency of dopamine (D2) receptor blockade and the duration of treatment. **1. Why Olanzapine is correct:** Olanzapine is a **Second-Generation Antipsychotic (SGA)** or atypical antipsychotic. Atypical antipsychotics have a lower affinity for D2 receptors and a higher affinity for 5-HT2A receptors. They also exhibit "fast dissociation" from D2 receptors. These properties significantly reduce the risk of Extrapyramidal Side Effects (EPS) and long-term complications like Tardive Dyskinesia compared to First-Generation Antipsychotics (FGAs). Among the options provided, Olanzapine carries the lowest risk of inducing TD. **2. Why the other options are incorrect:** * **Flupenthixol (Option A):** This is a typical (First-Generation) antipsychotic of the thioxanthene class. It is a potent D2 receptor antagonist and is associated with a significantly higher risk of TD. * **Penfluridol (Option B):** This is a long-acting oral typical antipsychotic. Due to its high potency and long half-life, it maintains a sustained blockade of D2 receptors, making the risk of TD much higher than with atypical agents. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** TD is characterized by involuntary choreoathetoid movements, most commonly involving the orofacial region (e.g., tongue protrusion, lip-smacking). * **Pathophysiology:** It is thought to be caused by **dopamine receptor supersensitivity** in the nigrostriatal pathway following chronic blockade. * **Drug of Choice for TD:** If TD develops, the offending agent should be switched to **Clozapine** (the antipsychotic with the lowest overall risk of TD). * **FDA-Approved Treatment:** **VMAT-2 inhibitors** (e.g., Valbenazine, Deutetrabenazine) are now the standard treatment for managing TD symptoms. * **Risk Hierarchy:** Clozapine < Quetiapine < Olanzapine < Risperidone < Typical Antipsychotics (Haloperidol).

Question 1

What is the therapeutic serum level of lithium in acute mania?

Accepted Answer

0.8-1.5 mEq/L

Answer

0.2-0.5 mEq/L

Answer

1-2 mEq/L

Answer

2-5 mEq/L

Question 2

The procedure shown below is used in all of the following illnesses except:

Accepted Answer

Dissociative disorder

Answer

Catatonic schizophrenia

Answer

Treatment-resistant major depressive disorder

Answer

Severe mania

Question 3

A 28-year-old woman with bipolar disorder has a lithium level of 2.3 mEq/L (normal range 0.6-1.25 mEq/L). Which of the following side effects is most likely to occur?

Accepted Answer

tremor

Answer

mania

Answer

depression

Answer

hyponatremia

Question 4

Raj Mohan has recently been on an increased regime of antipsychotics for Schizophrenia. Which of the following complications is NOT associated with the combined use of more than one antipsychotic?

Accepted Answer

Renal Tubular Necrosis

Answer

Neuroleptic Malignant Syndrome

Answer

Paralytic ileus

Answer

QTc Prolongation in ECG

Question 5

A 60-year-old male presents with profound guilt, believing he has committed sins throughout his life. He exhibits depressive symptoms and has contemplated suicide. He has sought guidance from a spiritual guru and is resistant to reassurance from his wife about his virtuous life. How would you manage this patient?

Accepted Answer

Antipsychotic combined with antidepressant

Answer

Antidepressant monotherapy

Answer

Antidepressant combined with cognitive behavioral therapy

Answer

Antidepressant with continued spiritual guidance and counseling

Question 6

Who introduced lithium for the treatment of manic-depressive illness?

Accepted Answer

John F. Cade

Answer

Benedict Morel

Answer

Delay and Deniker

Answer

Bleuler

Question 7

Which of the following drugs are used for recurrent depressive episodes?

Accepted Answer

Fluoxetine

Answer

Imipramine

Answer

Carbamazepine

Answer

Valproate

Question 8

Which of the following conditions increases the chance of hyponatremia in a patient treated with an antidepressant?

Accepted Answer

Old age

Answer

Low weight

Answer

Cold climate

Answer

Obesity

Question 9

What adverse effect can sodium valproate cause in a patient with bipolar mood disorder?

Accepted Answer

Hepatotoxicity

Answer

Peripheral neuropathy

Answer

Renal failure

Answer

Cystitis

Question 10

Tardive dyskinesia is least common with which of the following medications?

Accepted Answer

Olanzapine

Answer

Flupenthixol

Answer

Penfluridol

Answer

None of the above

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?